Prof. Dr. med. Gunnar Cario

Facts

Phone: +49-431-500-20106
Affiliations: Clinic for Pediatrics and Adolescent Medicine I / University Medical Center Schleswig-Holstein, Campus Kiel
Address: Arnold-Heller-Str. 3, Bldg C, 24105 Kiel

Curriculum vitae

Education/Training

Since 2014Vice Director and Senior Attending Physician, Clinic for Pediatrics and Adolescent Medicine I, UKSH, Kiel
Since 2011Vice Director and Senior Attending Physician,Clinic for Pediatrics and Adolescent Medicine I, UKSH, Kiel
2011Certification for Pediatric Hematology and Oncology, Board of Physicians Schleswig- Holstein
2008-2011Clinical Fellow, Clinic for Pediatrics and Adolescent Medicine I, Pediatric Hematology/Oncology, UKSH, Kiel
2008Certification for Pediatrics, Board of Physicians Schleswig-Holstein
2006-2008Internship/Residency, Clinic for Pediatrics and Adolescent Medicine I, UKSH, Kiel
2000-2005Internship/Residency, Department of Pediatrics, MHH
1993-2000Medical School, Hannover Medical School (MHH), Hannover

Research Experience/Academic Appointments

Since 2020Full Professor for Pediatric Oncology, University of Kiel
2017-2019APL-Professor in Pediatrics, University of Kiel
Since 2017National chair, EsPhALL2017/COGAALL1631 study
Since 2016Vice chair ALL-BFM study group
2011-2015Task force leader, European Network for Cancer Research in Children and Adolescents (ENCCA)
2010Habilitation in Pediatrics, University of Kiel
Since 2009Research coordinator ALL-BFM study group
2008-2013Project leader National cancer research network (NGFN), Verbundprojekt Leukämien
2000MD thesis, Hannover Medical School

Important Scientific Prizes/Functions

2005Junior Award of the German Society of Pediatric Oncology and Hematology
1996-2000Stipend of the Studienstiftung des Deutschen Volkes

Project-related publications

P1, P3, P6, P7, Z

The IL-7R antagonist Lusvertikimab reduces leukemic burden in xenograft-ALL via antibody-dependent cellular phagocytosis

Lenk L, Baccelli I, Laqua A, Heymann J, Reimer C, Dietterle A, Winterberg D, Mary C, Corallo F, Taurelle J, Narbeburu E, Neyton SL, Déramé M, Pengam S, Vogiatzi F, Bornhauser B, Bourquin JP, Raffel S, Dovhan V, Schüler T, Escherich G, den Boer ML, Boer JM, Wessels W, Peipp M, Alten J, Antić Ž, Bergmann AK, Schrappe M, Cario G, Brüggemann M, Poirier N, Schewe DM.

P1, P3, P4, INF, Z

The Gene Expression Classifier ALLCatchR Identifies B-cell Precursor ALL Subtypes and Underlying Developmental Trajectories Across Age

Beder T, Hansen BT, Hartmann AM, Zimmermann J, Amelunxen E, Wolgast N, Walter W, Zaliova M, Antić Ž, Chouvarine P, Bartsch L, Barz MJ, Bultmann M, Horns J, Bendig S, Kässens J, Kaleta C, Cario G, Schrappe M, Neumann M, Gökbuget N, Bergmann AK, Trka J, Haferlach C, Brüggemann M, Baldus CD, Bastian L.

HemaSphere
2023
P1, P3, P4, Z, INF

Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL.

Bastian L, Beder T, Barz MJ, Bendig S, Bartsch L, Walter W, Wolgast N, Brändl B, Rohrandt C, Hansen BT, Hartmann AM, Iben K, Das Gupta D, Denker M, Zimmermann J, Wittig M, Chitadze G, Neumann M, Schneller F, Fiedler W, Steffen B, Stelljes M, Faul C, Schwartz S, Müller FJ, Cario G, Harder L, Haferlach C, Pfeifer H, Gökbuget N, Brüggemann M, Baldus CD.

P1, Z

Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study

Boer ML*, Cario G*, Moorman AV*, Boer JM, de Groot-Kruseman HA, Fiocco M, Escherich G, Imamura T, Yeoh A, Sutton R, Dalla-Pozza L, Kiyokawa N, Schrappe M, Roberts KG, Mullighan CG, Hunger SP, Vora A, Attarbaschi A, Zaliova M, Elitzur S, Cazzaniga G, Biondi A, Loh ML, Pieters R.

*equally contributing first authors.

The Lancet Haematology
2021
P1, P6, Z

IKZF1 plus Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia

Stanulla M, Dagdan E, Zaliova M, Möricke A, Palmi C, Cazzaniga G, Eckert C, Te Kronnie G, Bourquin JP, Bornhauser B, Koehler R, Bartram CR, Ludwig WD, Bleckmann K, Groeneveld-Krentz S, Schewe D, Junk SV, Hinze L, Klein N, Kratz CP, Biondi A, Borkhardt A, Kulozik A, Muckenthaler MU, Basso G, Valsecchi MG, Izraeli S, Petersen BS, Franke A, Dörge P, Steinemann D, Haas OA, Panzer-Grümayer R, Cavé H, Houlston RS, Cario G, Schrappe M, Zimmermann M

TRANSCALL Consortium; International BFM Study Group.

J Clin Oncol
2018

Participating Institutes